2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2006
Rapid Hypoxia Preconditioning Protects Cortical Neurons From Glutamate Toxicity Through δ-Opioid Receptor
Zhang J, Qian H, Zhao P, Hong SS, Xia Y. Rapid Hypoxia Preconditioning Protects Cortical Neurons From Glutamate Toxicity Through δ-Opioid Receptor. Stroke 2006, 37: 1094-1099. PMID: 16514101, DOI: 10.1161/01.str.0000206444.29930.18.Peer-Reviewed Original ResearchConceptsDelta-opioid receptorsHypoxia preconditioningCortical neuronsNeuronal injuryGlutamate-induced neuronal injuryCultured rat cortical neuronsReceptor bindingSevere hypoxic injurySevere neuronal injuryRT-PCRCultured cortical neuronsMRNA levelsNMDA receptor expressionRat cortical neuronsΔ-opioid receptorsDOR mRNA levelsCulture day 8Short-term hypoxiaDOR mRNALactate dehydrogenase leakageHypoxic injuryGlutamate toxicityNeuronal viabilityReceptor expressionNeuroprotection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply